The present invention relates to a method of calculating a proton density fat fraction, PDFF, from a water and fat separated magnetic resonance imaging, MRI, based on fat-referenced lipid quantification in a region of interest (ROI) and using determination of a reference tissue. The method comprises the step of determining: F·βf/R, wherein F is the fat signal in the ROI provided from the MRI, βf is a function providing a ratio between T1 saturation values of the fat signals in the reference tissue and in the ROI; and R is a representation of the sum of fat and water signals on an intensity scale where the saturation of each of the fat and water signals equals the saturation of fat in the reference tissue.
|
1. A method of calculating a proton density fat fraction, PDFF, from a water, W, and fat, F, separated magnetic resonance imaging, MRI, based on fat-referenced lipid quantification in a region of interest (ROI) and using determination of a reference tissue, the method comprising the step of determining PDFF as:
wherein
F is the fat signal in the ROI provided from the MRI,
βf is a function providing a ratio between T1 saturation factors of the fat signals in the reference tissue and in the ROI; and
R is a representation of the sum of the unsaturated fat and water signals after this sum has been saturated by the saturation factor for fat in the reference tissue.
2. A proton density fat fraction, PDFF, calculation apparatus comprising:
a receiver configured to receive a water, W, and fat, F, separated magnetic resonance imaging, MRI; and
a processor configured to, based on the received water and fat separated MRI, and based on fat-referenced lipid quantification in a region of interest (ROI) and using determination of a reference tissue, determine the PDFF as
wherein
F is the fat signal in the ROI provided from the MRI,
βf is a function providing a ratio between T1 saturation factors of the fat signals in the reference tissue and in the ROI; and
R is a representation of the sum of the unsaturated fat and water signals after this sum has been saturated by the saturation factor for fat in the reference tissue.
3. Method according to
wherein
Fref is the fat signal in the reference tissue; and
PDFFrefis the PDFF of the reference tissue provided by a separate experiment of the reference tissue or by a predetermined constant.
4. The method according to
5. The method according to
wherein
F2PD is the observed fat signal in the ROI, being a reconstruction of the fat signal from the MRI in the ROI using two-point Dixon acquisition;
Tip is a constant of the echo time of the in-phase (IP) component comprising water plus fat signal of the water and fat signals from the MRI in the ROI;
T2*w is the T2* relaxation effect of water in the ROI resulting from the two-point Dixon analysis;
Top is a constant of the echo time of the out-of-phase (OP) component comprising the difference between the water and fat signals from the MRI in the ROI; and
F2PD, ref is the observed fat signal of the reference tissue, being a reconstruction of the fat signal from the MRI in the reference tissue using two-point Dixon acquisition.
6. The method according to
7. The method according to
8. The method according to
wherein βf is the quota of
wherein α is the effective flip angle in the MRI acquisition, TR is the repetition time, T1f,ref is the T1 value for the fat signal in the reference tissue, and T1f,ROI is the T1 value for the fat signal in the ROI.
9. The method according to
10. The method according to
wherein
W is the water signal in the ROI provided by the MRI; and
βw is a function providing a ratio between the T1 saturation factor of the fat signal in the reference tissue and the T1 saturation factor of the water signal in the ROI.
11. The method according to
wherein PDFFex is the proton density fat fraction measured in a separate experiment.
12. The method according to
13. The apparatus according to
wherein
Fref is the fat signal in the reference tissue; and
PDFFref is the PDFF of the reference tissue provided by a separate experiment of the reference tissue or by a predetermined constant.
14. The apparatus according to
15. The apparatus according to
wherein
F2PD is the observed fat signal in the ROI, being a reconstruction of the fat signal from the MRI in the ROI using two-point Dixon acquisition;
Tip is a constant of the echo time of the in-phase (IP) component comprising water plus fat signal of the water and fat signals from the MRI in the ROI;
T2*w is the T2* relaxation effect of water in the ROI resulting from the two-point Dixon analysis;
Top is a constant of the echo time of the out-of-phase (OP) component comprising the difference between the water and fat signals from the MRI in the ROI; and
F2PD,ref is the observed fat signal of the reference tissue, being a reconstruction of the fat signal from the MRI in the reference tissue using two-point Dixon acquisition.
16. The apparatus according to
17. The apparatus according to
18. The apparatus according to
wherein βf is the quota of
wherein α is the effective flip angle in the MRI acquisition, TR is the repetition time, T1f,ref is the T1 value for the fat signal in the reference tissue, and T1f,ROI is the T1 value for the fat signal in the ROI.
19. The apparatus according to
20. The apparatus according to
wherein
W is the water signal in the ROI provided by the MRI; and
βw is a function providing a ratio between the T1 saturation factor of the fat signal in the reference tissue and the T1 saturation factor of the water signal in the ROI.
21. The apparatus according to
wherein PDFFex is the proton density fat fraction measured in a separate experiment.
22. The apparatus according to
|
This application claims priority to International Application No. PCT/EP2018/054488, filed Feb. 23, 2018 and titled “MRI METHOD FOR CALCULATING A PROTON DENSITY FAT FRACTION,” which in turn claims priority from a European Patent Application having serial number 17181641.6, filed Jul. 17, 2017, titled “CALCULATION OF T2* CORRECTED PDFF,” both of which are incorporated herein by reference in their entireties.
The present disclosure relates to calculation of proton density fat fraction (PDFF) magnetic resonance imaging (MRI) based on fat-referenced lipid quantification.
Non-alcoholic fatty liver disease (NAFLD), a range of diseases characterized by steatosis, is associated with metabolic syndrome, diabetes, and obesity (Ekstedt et al., 2006; Ertle et al., 2011) and can lead to advanced fibrosis, cirrhosis, and hepatocellular carcinoma (Ekstedt et al., 2006; Wattacheril et al., 2012). Non-alcoholic steatohepatitis, a more serious form of NAFLD, is now the single most common cause of liver disease in developed countries (Sanyal, 2011; Misra et al., 2009) and is associated with high rates of morbidity and mortality. The evaluation and grading of hepatocellular fat in patients with NAFLD usually requires a liver biopsy and histology. However, as liver biopsy is an expensive, invasive, and painful procedure that is sensitive to sampling variability (Hubscher, 2006; Wieckowska et al. 2008), imaging modalities, including magnetic resonance spectroscopy (MRS) and MRI, are frequently being adopted to determine proton density fat fraction (PDFF). PDFF-MRS is a noninvasive and accurate method for quantification of hepatic fat content, but it has proven difficult to implement in clinical practice owing to its expense and dependence on specific expertise. Further, the method only gives a local estimate of the liver fat content (Reeder et al., 2010). Multi-echo MRI-determined PDFF imaging provides non-local, quantitative, standardized measurements of hepatic fat that is reproducible and correlates closely with MRS (Noureddin 2013; Kamg 2011), liver biopsy (Tang et al., 2013) and ex vivo measurements (Bannas et al., 2015).
Traditional quantitative fat-fraction analysis using the two point Dixon (2PD) technique, which is based on acquisition of out-of-phase and in-phase images, has been shown to be useful to evaluate hepatic fat (Dixon, 1984; Glover, 1991; Qayyum et al., 2005; Pilleul et al., 2005; Reeder et al., 2005; Reeder & Sirlin, 2010). The disadvantage of 2PD in relation to multi-echo Dixon is that T2* has to be determined in a separate experiment. But, in essence, both dual and multi echo Dixon shares the same confounding factors that influence MRI signal intensity, including T2* decay, spectral complexity of hepatic fat, and T1-saturation bias (Reeder et al., 2011; Chebrolu et al., 2010). While the first three factors can be reduced through signal modeling, T1-saturation bias is commonly avoided using a low flip angle since the alternative, long repetition times, results in unfeasible breath-hold times. However, a low flip angle is associated with a low signal-to-noise-ratio (SNR), leading to reduced sensitivity in liver PDFF imaging (Johnson et al., 2014). This complicates the trade-off between image voxel size, breath-hold length, and SNR. Furthermore, as the SNR decreases, proper coil positioning becomes more important, especially in obese patients, and this makes clinical translation of the technique more difficult.
By increasing the flip angle, and thereby transforming the acquisition into a T1-saturated state, the trade-off between voxel size, breath-hold length, and desired level of SNR becomes less critical (Kühn et al., 2014). However, the T1 weighting causes a bias in the measured signals unless corrected (Fleysher et al., 2009). It is possible to adaptively measure and compensate for the T1 bias using a more complex experiment, as has been demonstrated by Kuhn and colleagues (Kuhn et al., 2014). Applying such correction to three-dimensional (3D) acquisitions is straightforward if the T1 values of the fat and water tissue are well characterized. Nevertheless, the specific characteristics of the MR pulse sequence implementation and uncertainty in quantification of the T1 of water and fat may influence the validity of the signal equations and lead to residual T1 bias.
Fat-referenced lipid quantification allows fat quantification in T1-weighted Dixon imaging, and was originally introduced by Hu and colleagues and Dahlqvist Leinhard and colleagues (Hu and Nayak, 2008; Dahlqvist Leinhard et al., 2008). This quantification method calibrates the observed signal intensities of the water and fat images using the lipid signal in pure adipose tissue. This transforms the Dixon images into a common intensity scale where a value of 1 in the fat image corresponds to an adipose tissue concentration of 100%. The invariability to the T1 weighting has been shown by Peterson et al. (Peterson et al., 2016). In that study, intramuscular adipose tissue quantification using the fat-referenced technique was validated against conventional low-flip-angle PDFF estimation with a very high agreement between the methods. Recently, Andersson and colleagues further validated the fat-referenced technique in whole-body imaging at both 1.5 T and 3.0 T for bias field estimation in skeletal muscle and liver tissue (Andersson et al., 2015). Further, Heba and colleagues determined that the accuracy of magnitude-based MRI for estimating hepatic PDFF using MRS as a reference was unchanged when using different numbers of echoes and was unaffected by possible subject-based confounders (Heba et al., 2016).
As discussed above, there is a need for a framework for calculation of PDFF of for instance a liver. It is an object of the present invention to provide such framework for calculation of PDFF based on T1-weighted two-point and multipoint Dixon imaging according to the appended independent claims. Embodiments of the present invention are provided by the accompanying independent claims. The present invention thereby provides technology for accurate estimation of organ PDFF using fat-referenced Dixon imaging, either via correction using the saturation ratio between the fat and water signal, or by direct use of fat estimates obtained following fat-referencing. This is especially relevant for estimation of liver PDFF for diagnosis and treatment of decreases as discussed above.
By calculating a PDFF it may be meant that in the method according to the present invention the reconstruction of fat and water images may, or may not, be corrected for T2* effects and/or spectral dispersion effects due to characteristics of the lipid spectrum, or the reconstruction.
The PDFF calculation apparatus configured to perform the PDFF calculations may be constituted by a computer comprising the necessary computer executable program and provided with the necessary input for the calculations.
The present invention and its embodiments provide that accurate proton density fat fraction (PDFF) estimation may be achieved in T1-weighted fat- and water-separated imaging using the presented framework based on fat-referenced fat quantification. The present invention provides that two-point Dixon (2PD) magnetic resonance imaging (MRI) using simplistic reconstruction without a multispectral lipid model may be used for accurate liver PDFF estimation using fixed T2* correction. This may further be improved by taking the individual T2* values of the liver water signal into account. But this is also applicable to other organs in the human body.
The fat-referenced quantification technique shows much lower sensitivity to T2* effects in 2PD PDFF calculations compared to the 2PD fat fraction technique. This lowered sensitivity to T2* relaxation is achieved because the fat referenced calculations do not include the water signal in the denominator.
The present invention provides that PDFF may be accurately estimated using T1 saturation corrected 10PD acquisitions using the suggested approach. Limits of agreement of ±1.41% for liver PDFF acquired with different sequences, in different breath holds, and with different acquisition coils in the datasets fulfilling strict quality control and ±1.44% in the analysis including all datasets may be achieved with the present invention, which are lower than what is commonly observed using other state of the art implementations.
The findings of using the present invention may be compared with those of the recent study by Heba and colleagues, in their retrospective analysis of 506 adults with non-alcoholic fatty liver disease (NAFLD), where liver PDFF was estimated using unenhanced 3.0T MRI, using right liver lobe magnetic resonance spectroscopy (MRS) as a reference (Heba et al. 2016). In this previous study, PDFF MRI findings were in close agreement with magnetic resonance spectroscopy (MRS), with the two-echo method based on fat fraction measurement with spectral correction but without T2* correction being least accurate. (Heba et al. 2016).
The present invention provides an alternative way to compensate for effects caused by the hepatic lipid spectrum. Correction of the lipid spectrum based on the acquired data, is normally a complex process, especially as the analysis also involves estimation of lipid T2* and water T2* relaxation (Qayyum et al. 2005; Reeder et al. 2011; Hu et al. 2011). Here, no assumptions have been made about the details of the lipid spectrum model. Using the methods described herein, the only basic assumptions made are that in-phase and opposite-phase imaging creates a highly specific contrast for fat and water, and that the effects on the observed lipid signal caused by the lipid spectrum are similar in both the reference adipose tissue and in the liver tissue.
According to a first aspect of the invention, a method of calculating a proton density fat fraction, PDFF, from a water, W, and fat, F, separated magnetic resonance imaging, MRI, based on fat-referenced lipid quantification in a region of interest (ROI) and using determination of a reference tissue is provided. The method comprises the step of determining PDFF as:
wherein
F is the fat signal in the ROI provided from the MRI,
βf is a function providing a ratio between T1 saturation values of the fat signals in the reference tissue and in the ROI; and
R is a representation of the sum of fat and water signals on an intensity scale where the saturation of each of the fat and water signals equals the saturation of fat in the reference tissue.
The method may be described as comprising the fat signal in the ROI provided from the MRI multiplied with βf being a function providing a ratio between T1 saturation value of the fat signals in the reference tissue and in the ROI, wherein the product thereof is divided with R being a representation of the signal intensity of the sum of fat and water on an intensity scale where fat and water are saturated with the saturation level only affecting the fat signal extrapolated from the reference tissue.
In one embodiment, the method may further comprise a step of determining the T1 saturation value of the fat signal in the reference tissue. Alternatively, such determination is premade and the method may comprise a step of receiving a T1 saturation value of the fat signal in the reference tissue. Further, the method may in one embodiment comprise a step of determining a T1 saturation value of the fat signal in the ROI, to be used for βf in the determination of PDFF, or alternatively a step of receiving such T1 saturation value of the fat signal in the ROI.
In one embodiment, the method may comprise a step of receiving a value of R as defined above, for the determination of PDFF. Alternatively, the method may comprise a step of receiving input for the determination of R, and a step of determining R based on said input.
In one embodiment, R may provide a quota between Fref and PDFFref such that the method comprises the step of determining PDFF as:
wherein
Fref is the fat signal in the reference tissue; and
PDFFref is the PDFF of the reference tissue provided by a separate experiment of the reference tissue or by a predetermined constant.
The method according to this embodiment may further be described as the quota between F and Fref being the fat signal in the reference tissue, multiplied with βf and PDFFref being the PDFF of the reference tissue provided by a separate experiment of the reference tissue or by a predetermined constant. The values of PDFFref and Fref may in one embodiment be received in a step of the method to be used for the determination of PDFF.
In another embodiment, the T1 saturation values of the fat signal in the reference tissue and in the ROI may be equal, providing βf=1.
In a further embodiment, the PDFF may be determined from a fat-referenced two-point Dixon acquisition without previous correction for T2* relaxation effects, and the water signal in the reference tissue, Wref, may be low such that a resulting value when Wref is multiplied with a resulting T2* relaxation effect provides an approximation that the water signal in the ROI equals an observed water signal in the ROI, W2PD, being a reconstruction of the water signal from the MRI in the ROI using two-point Dixon acquisition, providing the PDFF to be determined as
wherein
F2PD is the observed fat signal in the ROI, being a reconstruction of the fat signal from the MRI in the ROI using two-point Dixon acquisition;
Tip is a constant of the echo time of the in-phase (IP) component comprising water plus fat signal of the water and fat signals from the MRI in the ROI;
T2*w is the T2* relaxation effect of water in the ROI resulting from the two-point Dixon analysis;
Top is a constant of the echo time of the out-of-phase (OP) component comprising the difference between the water and fat signals from the MRI in the ROI; and
F2PD, ref is the observed fat signal of the reference tissue, being a reconstruction of the fat signal from the MRI in the reference tissue using two-point Dixon acquisition. In one embodiment, the method may comprise a step of receiving the F2PD and F2PD, ref signal values to be used for the PDFF determination. In one embodiment, the method may comprise a step of receiving the Top and Tip time values to be used for the PDFF determination. In one embodiment, the method may comprise a step of receiving the T2*w value to be used for the PDFF determination.
In one embodiment, the T2* relaxation effect value may be determined in a separate experiment.
In another embodiment, the T2* relaxation effect value may be set as a constant based on a population mean.
In a further embodiment, βf may be the quota of
wherein α is the effective flip angle in the MRI acquisition, TR is the repetition time, T1f,ref is the T1 value for the fat signal in the reference tissue, and T1f,ROI is the T1 value for the fat signal in the ROI. In one embodiment, the method may comprise a step of receiving the TR, T1f,ref and T1f,ROI values to be used for the PDFF determination.
In another embodiment, the Fref may be determined as a weighted interpolation of the fat signal in the reference tissue. Further, to provide such weighted interpolation of the fat signal in the reference tissue, a method as presented in “Romu T, Borga M, Dahlqvist Leinhard O. MANA—multiscale adaptive normalized averaging. In: Proceedings of the IEEE International Symposium on Biomedical Imaging: From Nano to Macro, Chicago, Ill., USA, 2011. pp 361-364” may be used.
In one embodiment, R may be defined as F·βf+W·βw, and wherein the T1 saturation value of the fat signal in the reference tissue and in the ROI is equal, providing βf=1, providing the method comprising the step of determining PDFF as
wherein
W is the water signal in the ROI provided by the MRI; and
βw is a function providing a ratio between the T1 saturation value of the fat signal in the reference tissue and the T1 saturation value of the water signal in the ROI. In one embodiment, the method may further comprise a step of determining the T1 saturation value of the fat signal in the reference tissue. Alternatively, such determination is premade and the method may comprise a step of receiving a T1 saturation value of the fat signal in the reference tissue. Further, the method may in one embodiment comprise a step of determining a T1 saturation value of the fat signal in the ROI, to be used for βw in the determination of PDFF. Alternatively, such determination is premade and the method may comprise a step of receiving a T1 saturation value of the fat signal in the ROI.
In a further embodiment, βw may be determined in a separate experiment by determining
wherein PDFFex is the proton density fat fraction measured in a separate experiment. The PDFFex measured in a separate experiment may preferably, but not necessarily, be made in the same subject as the PDFF calculation in which the βw to be determined is to be used.
In a yet further embodiment, PDFF may be provided by a separate 2-point Dixon experiment. The equation to determine βw may then be provided by determining
According to a second aspect of the invention, a proton density fat fraction, PDFF, calculation apparatus is provided, wherein the calculation apparatus comprises a receiver and a processor. The receiver may be configured to receive a water, W, and fat, F, separated magnetic resonance imaging, MRI. The processor may be configured to, based on the received water and fat separated MRI, and based on fat-referenced lipid quantification in a region of interest (ROI) and using determination of a reference tissue, determine the PDFF as
wherein
F is the fat signal in the ROI provided from the MRI,
βf is a function providing a ratio between T1 saturation values of the fat signals in the reference tissue and in the ROI; and
R is a representation of the sum of fat and water signals on an intensity scale where the saturation of each of the fat and water signals equals the saturation of fat in the reference tissue. The receiver and the processor may further be configured to receive entities and perform determinations according to any of the embodiments described above. As seen in
The invention will in the following be described in more detail with reference to the enclosed drawings, wherein:
The present invention will be described more fully hereinafter according to preferred embodiments of the invention. This invention may, however, be embodied in many different forms and should not be construed as limited to the embodiments set forth herein; rather, these embodiments are provided so that this disclosure will be thorough and complete, and will fully convey the scope of the invention to those skilled in the art.
Signal Model
In spoiled gradient echo water-fat separated image reconstruction after taking T2* and lipid spectrum effects into account, the water (W) and fat (F) signals can be represented by the following equations:
where Wunsat and Funsat are the unsaturated water and fat signals, and sw and sf are the water- and fat-saturation factors that are dependent on the local flip angle α, the repetition time TR and the tissue dependent T1 values, T1w and T1f, for water and fat. Note that the exact value of a is unknown as it is dependent on prescan performance and on the characteristics of the radiofrequency pulse profile.
To quantify the fat content of a tissue, the unsaturated Funsat is insufficient as it is dependent on a range of unknown factors, besides the number of fat protons. Proton density fat fraction (PDFF) is a quantitative fat-content technique that is invariant to these unknown factors. In PDFF imaging Funsat is calibrated using a unsaturated in-phase signal reference, IPunsat=Funsat+Wunsat, e.g. PDFF is defined as:
Because the multiplicative factors are identical in Funsat and IPunsat, PDFF is the fraction of MRI visible fat protons in relation to the sum of MRI visible fat and water protons. Furthermore, as PDFF is based on the unsaturated MRI signals, the acquisition parameters must be set such that sw≈sf, e.g. by choosing a low flip angle. Alternatively, additional images need to be collected to determine the ratio between and sw and sf.
An alternative quantitative technique is fat-referenced MRI where F is calibrated using a fat signal Fref (Romu et al., 2011; Dahlqvist Leinhard et al., 2008). The benefit is that this measurement is invariant to the water and fat saturations given that Fref is affected by the same sf as F. However, the fat-referenced signal corresponds to the number of fat protons in the measurement point relative to the number of fat protons in the reference, and is thus not identical to PDFF. To translate the fat-reference signal to PDFF, assume that there exists an in-phase reference, R, which saturates with a fat saturation factor, sf,R, e.g.:
R=IPunsatsf,R· [equation 4]
Then, the PDFF equation can be expressed as:
where the factor
corrects for any difference in saturation between the measured fat signal and the reference. Also note that if the saturation of R is similar to that of the fat signal, then βf≈1.
Relating the Fat-Referenced Signal to PDFF
In fat-referenced lipid quantification, a signal reference is acquired from regions of pure adipose tissue within the subject and interpolated over the complete image volume (Romu et al., 2011; Dahlqvist Leinhard et al., 2008). To convert the fat-referenced signal to PDFF, let Fref represent the fat signal of the reference tissue, and set the saturation of R to the saturation level of Fref, i.e. sf,ref=sf,R. Thus, the PDFF of the reference tissue is equal to Fref·R−1, so R=Fref·PDFFref−1, and eq. 5 describing PDFF in the measurement point can therefore be reformulated as (see
where F·Fref−1 is the fat-referenced signal, e.g. the raw fat signal calibrated by the interpolated fat reference signal. This is further illustrated in
The consequence of Eq. 7 is that the calibrated fat signal in the fat-referenced analysis can be converted to PDFF by adjusting for the PDFF in the adipose reference tissue and for any difference in fat saturation relative to the reference. Furthermore, if the fat saturation is similar to the reference, then the fat-referenced PDFF can be computed as:
Adjusting for Effects Occurring in Two-Point Dixon (2PD) Imaging
In 2PD analysis, using simplistic reconstruction of the fat and water image components after phase-sensitive reconstruction of the OP image, the observed fat signal is given by
where tf+ is a function of the fat T2*-relaxation, T2,f*, the spectral dispersion of fat, d, and the echo times Top and Tip. Similarly, tw− describes the crosstalk caused by the water signal as a function of T2,w* and the echo times Top and Tip. Similarly, the observed water signal is given by
Solving for the PDFF in Eq. 8, with the corresponding signal estimated using two-point Dixon imaging, gives
Furthermore, since F2PD,ref»Wref·tw,ref− in adipose tissue and assuming similar T2* effects F2PD and F2PD,ref, i.e. tf+≈tf,ref+, Eq. 11 can be approximated to:
where T2,w*, and PDFFref are the only unknowns.
Quantification of PDFF in T1-Saturated Dixon Imaging
Two different implementations for PDFF quantification in T1-saturated Dixon imaging can be used.
Implementation 1. Fat-Referenced Dixon Imaging with Correction for Effects of T2* Relaxation and Adipose Tissue Water Concentration.
Assuming T1-saturated 2PD, such that the PDFF is given by Eq. 12. Furthermore, the values of T2,w* and PDFFref in Eq. 12 can either be determined on an individual level in a separate experiment, or assumed to be constant and set to a population mean.
Implementation 2. Water-Referenced T2*-Corrected Dixon Imaging with T1-Saturation Correction Based on Fat-Referenced Dixon Imaging.
If the saturation ratio between fat and water, βw=sf/sw, is known, the PDFF from a T1-saturated Dixon acquisition, corrected for T2* and spectral dispersion effects, is given by
The saturation ratio βw can then be determined based on a separate PDFF experiment, such as the fat referenced PDFF2PD, by minimizing the following expression with respect to βw,
which minimizes the observed differences between PDFF in the water-referenced acquisition and PDFF2PD from the fat-referenced T2*-corrected 2PD acquisition.
In the drawings and specification, there have been disclosed preferred embodiments and examples of the invention and, although specific terms are employed, they are used in a generic and descriptive sense only and not for the purpose of limitation, the scope of the invention being set forth in the following claims.
Patent | Priority | Assignee | Title |
Patent | Priority | Assignee | Title |
9194925, | Nov 05 2012 | SIEMENS HEALTHINEERS AG | Fat and iron quantification using a multi-step adaptive fitting approach with multi-echo magnetic resonance imaging |
JP2014091051, |
Executed on | Assignor | Assignee | Conveyance | Frame | Reel | Doc |
Feb 23 2018 | AMRA MEDICAL AB | (assignment on the face of the patent) | / | |||
Jan 17 2020 | LEINHARD, OLOF DAHLQVIST | AMRA MEDICAL AB | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 051582 | /0536 |
Date | Maintenance Fee Events |
Jan 16 2020 | BIG: Entity status set to Undiscounted (note the period is included in the code). |
Jan 23 2020 | SMAL: Entity status set to Small. |
Date | Maintenance Schedule |
Nov 01 2025 | 4 years fee payment window open |
May 01 2026 | 6 months grace period start (w surcharge) |
Nov 01 2026 | patent expiry (for year 4) |
Nov 01 2028 | 2 years to revive unintentionally abandoned end. (for year 4) |
Nov 01 2029 | 8 years fee payment window open |
May 01 2030 | 6 months grace period start (w surcharge) |
Nov 01 2030 | patent expiry (for year 8) |
Nov 01 2032 | 2 years to revive unintentionally abandoned end. (for year 8) |
Nov 01 2033 | 12 years fee payment window open |
May 01 2034 | 6 months grace period start (w surcharge) |
Nov 01 2034 | patent expiry (for year 12) |
Nov 01 2036 | 2 years to revive unintentionally abandoned end. (for year 12) |